Rottapharm stays quiet over stake sale rumours
This article was originally published in Scrip
Rottapharm has nothing to say about press rumours that its founding Rovati family is about to sell a 50% stake in the firm to private equity firms. A spokesperson for the Italian firm told Scrip that it had met funds in autumn 2011 "but nothing concrete had come of it" and the matter was closed.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.